{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T15:01:46Z","timestamp":1790089306875,"version":"4.0.1"},"reference-count":81,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Melanoma exhibits a marked predilection for central nervous system (CNS) dissemination, including both brain parenchymal metastases and leptomeningeal metastases (LMM), which together represent a major cause of morbidity and mortality. Historically characterized by poor prognosis, CNS melanoma has undergone a paradigm shift in management over the last decade with the advent of immune checkpoint inhibitors and targeted therapies, as well as advances in local treatment modalities such as stereotactic radiosurgery. While outcomes for patients with melanoma brain metastases have significantly improved, leptomeningeal melanoma metastases remain a devastating condition with limited evidence-based therapeutic options. This review provides a comprehensive and up-to-date overview of the epidemiology, biological determinants, diagnostic strategies, and therapeutic management of melanoma with cerebral and leptomeningeal involvement. Particular emphasis is placed on systemic treatment strategies, including immune checkpoint inhibitors, BRAF\/MEK-targeted therapies, and their integration with local treatments. Dedicated attention is given to leptomeningeal disease, highlighting emerging data on systemic immunotherapy, intrathecal approaches, and innovative therapeutic strategies aimed at overcoming the blood\u2013brain and blood\u2013CSF barriers. Finally, we address current challenges, unmet clinical needs, and future perspectives, including biomarker development, novel agents, and rational combination strategies, with the goal of improving outcomes for this high-risk population.<\/jats:p>","DOI":"10.3389\/fonc.2026.1874139","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T14:21:53Z","timestamp":1790086913000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Current and emerging strategies for the management of brain and leptomeningeal metastases in melanoma"],"prefix":"10.3389","volume":"16","author":[{"given":"Safa","family":"Idoudi","sequence":"first","affiliation":[{"name":"AP-HP Dermato-oncology and Centre d'Investigation Clinique (CIC), Cancer Institute APHP, Saint Louis Hospital","place":["Paris, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Billard","sequence":"additional","affiliation":[{"name":"AP-HP Dermato-oncology and Centre d'Investigation Clinique (CIC), Cancer Institute APHP, Saint Louis Hospital","place":["Paris, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilien","family":"Ezine","sequence":"additional","affiliation":[{"name":"AP-HP Dermato-oncology and Centre d'Investigation Clinique (CIC), Cancer Institute APHP, Saint Louis Hospital","place":["Paris, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Fournier","sequence":"additional","affiliation":[{"name":"AP-HP Dermato-oncology and Centre d'Investigation Clinique (CIC), Cancer Institute APHP, Saint Louis Hospital","place":["Paris, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolo","family":"Norri","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, AP-HP, Beaujon Hospital","place":["Clichy, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Decq","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, AP-HP, Beaujon Hospital","place":["Clichy, France"]},{"name":"Universit\u00e9 Paris Cit\u00e9","place":["Paris, France"]},{"name":"Georges Charpak Institute of Human Biomechanics, \u00c9cole Nationale Sup\u00e9rieure des Arts et M\u00e9tiers (ENSAM)","place":["Paris, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane","family":"Goutagny","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, AP-HP, Beaujon Hospital","place":["Clichy, France"]},{"name":"Universit\u00e9 Paris Cit\u00e9","place":["Paris, France"]},{"name":"Department of Radiation Oncology, Saint-Louis Hospital (AP-HP)","place":["Paris, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Nataf","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9","place":["Paris, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celeste","family":"Lebb\u00e9","sequence":"additional","affiliation":[{"name":"AP-HP Dermato-oncology and Centre d'Investigation Clinique (CIC), Cancer Institute APHP, Saint Louis Hospital","place":["Paris, France"]},{"name":"Universit\u00e9 Paris Cit\u00e9","place":["Paris, France"]},{"name":"Institut National De la Sant\u00e9 Et De la Recherche M\u00e9dicale (INSERM)","place":["Paris, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Faillot","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, AP-HP, Beaujon Hospital","place":["Clichy, France"]},{"name":"Universit\u00e9 Paris Cit\u00e9","place":["Paris, France"]},{"name":"Biomaps Research Laboratory, Commissariat \u00c1 l\u2019\u00c9nergie Atomique Et Aux \u00c9nergies Alternatives (CEA)","place":["Orsay, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nox077","article-title":"Incidence and prognosis of patients with brain metastases at diagnosis of systemic Malignancy: a population-based study","volume":"19","author":"Cagney","year":"2017","journal-title":"Neuro Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25634","article-title":"Prognostic factors for survival in melanoma patients with brain metastases","volume":"117","author":"Davies","year":"2011","journal-title":"Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0000000000000816","article-title":"Real-world data on melanoma brain metastases and survival outcome","volume":"32","author":"Pedersen","year":"2022","journal-title":"Melanoma Res"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00545-3","article-title":"Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study","volume":"22","author":"Tawbi","year":"2021","journal-title":"Lancet Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.0036","article-title":"NCCN guidelines\u00ae Insights: melanoma: cutaneous, version 2.2024","volume":"22","author":"Swetter","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/pcmr.12861","article-title":"Leptomeningeal disease in melanoma patients: An update to treatment, challenges, and future directions","volume":"33","author":"Glitza","year":"2020","journal-title":"Pigment Cell Melanoma Res"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-2681","article-title":"A population-level real-world analysis and single-center validation of melanoma brain metastasis epidemiology following dual-agent immunotherapy","volume":"31","author":"Bhanja","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605622","article-title":"Determinants of survival in patients with brain metastases from cutaneous melanoma","volume":"102","author":"Staudt","year":"2010","journal-title":"Br J Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25643","article-title":"Clinical variables and primary tumor characteristics predictive of the development of melanoma brain metastases and post-brain metastases survival","volume":"117","author":"Zakrzewski","year":"2011","journal-title":"Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1215\/15228517-2007-058","article-title":"Brain and leptomeningeal metastases from cutaneous melanoma: Survival outcomes based on clinical features","volume":"10","author":"Raizer","year":"2008","journal-title":"Neuro-Oncology"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-1027","article-title":"Complete loss of PTEN protein expression correlates with shorter time to brain metastasis and survival in stage IIIB\/C melanoma patients with BRAFV600 mutations","volume":"20","author":"Bucheit","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B12","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s12943-018-0854-5","article-title":"Deciphering mechanisms of brain metastasis in melanoma - the gist of the matter","volume":"17","author":"Redmer","year":"2018","journal-title":"Mol Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33459","article-title":"Melanoma brain metastasis presentation, treatment, and outcomes in the age of targeted and immunotherapies","volume":"127","author":"Bander","year":"2021","journal-title":"Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15061884","article-title":"Leptomeningeal disease (LMD) in patients with melanoma metastases","volume":"15","author":"Khaled","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.2214\/ajr.165.6.7484597","article-title":"Intracranial metastatic melanoma: correlation between MR imaging characteristics and melanin content","volume":"165","author":"Isiklar","year":"1995","journal-title":"Am J Roentgenology"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.4103\/2152-7806.111298","article-title":"Imaging of brain metastases","volume":"4","author":"Fink","year":"2013","journal-title":"Surg Neurol Int"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.07.016","article-title":"EANO-ESMO clinical practice guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours","volume":"32","author":"Le Rhun","year":"2021","journal-title":"Ann Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.101624","article-title":"Leptomeningeal metastasis from solid tumours: EANO-ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"8","author":"Le Rhun","year":"2023","journal-title":"ESMO Open"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/jnen\/nly046","article-title":"Evaluating circulating tumor DNA from the cerebrospinal fluid of patients with melanoma and leptomeningeal disease","volume":"77","author":"Ballester","year":"2018","journal-title":"J Neuropathol Exp Neurol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00088-1","article-title":"Immunotherapy response assessment in neuro-oncology: a report of the RANO working group","volume":"16","author":"Okada","year":"2015","journal-title":"Lancet Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noac043","article-title":"Prospective validation of a new imaging scorecard to assess leptomeningeal metastasis: A joint EORTC BTG and RANO effort","volume":"24","author":"Le Rhun","year":"2022","journal-title":"Neuro Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70057-4","article-title":"Response assessment criteria for brain metastases: proposal from the RANO group","volume":"16","author":"Lin","year":"2015","journal-title":"Lancet Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/now183","article-title":"Leptomeningeal metastases: a RANO proposal for response criteria","volume":"19","author":"Chamberlain","year":"2017","journal-title":"Neuro Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1007\/s11060-025-05274-9","article-title":"Multidisciplinary review outperforms qualitative MR perfusion in distinguishing post-radiation brain metastasis recurrence versus radionecrosis","volume":"176","author":"Toth","year":"2025","journal-title":"J Neuro-Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/now241","article-title":"Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO)","volume":"19","author":"Soffietti","year":"2017","journal-title":"Neuro Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30441-2","article-title":"Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C\/CEC\u00b73): a multicentre, randomised, controlled, phase 3 trial","volume":"18","author":"Brown","year":"2017","journal-title":"Lancet Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00141-2","article-title":"Evolving treatment options for melanoma brain metastases","volume":"16","author":"Ajithkumar","year":"2015","journal-title":"Lancet Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30414-X","article-title":"Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial","volume":"18","author":"Mahajan","year":"2017","journal-title":"Lancet Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2018.08.025","article-title":"Treatment of brain metastases with stereotactic radiosurgery and immune checkpoint inhibitors: An international meta-analysis of individual patient data","volume":"130","author":"Lehrer","year":"2019","journal-title":"Radiother Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2024.108069","article-title":"Immunotherapy or targeted therapy with or without stereotactic radiosurgery for patients with brain metastases from melanoma or non-small cell lung cancer - The ETOP 19-21 USZ-STRIKE study","volume":"199","author":"Weller","year":"2025","journal-title":"Lung Cancer"},{"key":"B31","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ejca.2020.04.028","article-title":"Stereotactic radiosurgery combined with anti-PD1 for the management of melanoma brain metastases: A retrospective study of safety and efficacy","volume":"135","author":"Carron","year":"2020","journal-title":"Eur J Cancer"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30138","article-title":"Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery","volume":"122","author":"Qian","year":"2016","journal-title":"Cancer"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.prro.2022.02.003","article-title":"Radiation therapy for brain metastases: An ASTRO clinical practice guideline","volume":"12","author":"Gondi","year":"2022","journal-title":"Pract Radiat Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.1206","article-title":"Clinical management of multiple melanoma brain metastases: A systematic review","volume":"1","author":"Goyal","year":"2015","journal-title":"JAMA Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01414","article-title":"Adjuvant whole-brain radiation therapy compared with observation after local treatment of melanoma brain metastases: A multicenter, randomized phase III trial","volume":"37","author":"Hong","year":"2019","journal-title":"J Clin Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0000000000000413","article-title":"Tolerance and outcomes of stereotactic radiosurgery combined with anti-programmed cell death-1 (pembrolizumab) for melanoma brain metastases","volume":"28","author":"Nardin","year":"2018","journal-title":"Melanoma Res"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2016.08.039","article-title":"Association between radiation necrosis and tumor biology after stereotactic radiosurgery for brain metastasis","volume":"96","author":"Miller","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noad188","article-title":"The dilemma of radiation necrosis from diagnosis to treatment in the management of brain metastases","volume":"26","author":"Mayo","year":"2024","journal-title":"Neuro Oncol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"10084","DOI":"10.1038\/s41598-020-67316-8","article-title":"Nationwide patterns of hemorrhagic stroke among patients hospitalized with brain metastases: influence of primary cancer diagnosis and anticoagulation","volume":"10","author":"Lee","year":"2020","journal-title":"Sci Rep"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2026.104045","article-title":"Bleeding complications of BRAF inhibitors","volume":"51","author":"Gurumurthy","year":"2026","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2024000660","article-title":"Management of anticoagulation in patients with brain metastasis","volume":"2024","author":"Hamuly\u00e1k","year":"2024","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1007\/s00066-025-02393-0","article-title":"Post-SRS haemorrhage and oncological outcome of patients with melanoma brain metastases undergoing stereotactic radiotherapy","volume":"201","author":"Schr\u00f6der","year":"2025","journal-title":"Strahlenther Onkol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70090-6","article-title":"Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial","volume":"13","author":"Margolin","year":"2012","journal-title":"Lancet Oncol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1200\/JCO.18.00204","article-title":"Long-term survival of patients with melanoma with active brain metastases treated with pembrolizumab on a phase II trial","volume":"37","author":"Kluger","year":"2019","journal-title":"J Clin Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001806","article-title":"KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma","volume":"8","author":"Ferrucci","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B46","doi-asserted-by":"publisher","first-page":"LBA9507","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA9507","article-title":"A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases: SWOG S2000 (NCT04511013)","volume":"43","author":"Eroglu","year":"2025","journal-title":"J Clin Oncol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"9520","DOI":"10.1200\/JCO.2021.39.15_suppl.9520","article-title":"Phase II study of TRIplet combination nivolumab (N) with dabrafenib (D) and trametinib (T) (TRIDeNT) in patients (pts) with PD-1 na\u00efve or refractory BRAF-mutated metastatic melanoma (MM) with or without active brain metastases","volume":"39","author":"Burton","year":"2021","journal-title":"J Clin Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805453","article-title":"Combined nivolumab and ipilimumab in melanoma metastatic to the brain","volume":"379","author":"Tawbi","year":"2018","journal-title":"N Engl J Med"},{"key":"B49","doi-asserted-by":"publisher","first-page":"9508","DOI":"10.1200\/JCO.2021.39.15_suppl.9508","article-title":"Five-year overall survival from the anti-PD1 brain collaboration (ABC Study): Randomized phase 2 study of nivolumab (nivo) or nivo+ipilimumab (ipi) in patients (pts) with melanoma brain metastases (mets)","volume":"39","author":"Long","year":"2021","journal-title":"J Clin Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00735-6","article-title":"Ipilimumab plus nivolumab versus nivolumab alone in patients with melanoma brain metastases (ABC): 7-year follow-up of a multicentre, open-label, randomised, phase 2 study","volume":"26","author":"Long","year":"2025","journal-title":"Lancet Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.07.004","article-title":"ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee","volume":"31","author":"Keilholz","year":"2020","journal-title":"Ann Oncol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102083","article-title":"Melanoma brain metastases - interdisciplinary management recommendations 2020","volume":"89","author":"Gutzmer","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"B53","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30429-1","article-title":"Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial","volume":"18","author":"Davies","year":"2017","journal-title":"Lancet Oncol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noae116","article-title":"Encorafenib and binimetinib followed by radiotherapy for patients with BRAFV600-mutant melanoma and brain metastases (E-BRAIN\/GEM1802 phase II study)","volume":"26","author":"M\u00e1rquez-Rodas","year":"2024","journal-title":"Neuro Oncol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01763","article-title":"Combination dabrafenib and trametinib versus combination nivolumab and ipilimumab for patients with advanced BRAF-mutant melanoma: the DREAMseq trial-ECOG-ACRIN EA6134","volume":"41","author":"Atkins","year":"2023","journal-title":"J Clin Oncol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02961","article-title":"Sequencing of ipilimumab plus nivolumab and encorafenib plus binimetinib for untreated BRAF-mutated metastatic melanoma (SECOMBIT): a randomized, three-arm, open-label phase II trial","volume":"41","author":"Ascierto","year":"2023","journal-title":"J Clin Oncol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12092635","article-title":"Impact of new systemic treatment and radiotherapy in melanoma patients with leptomeningeal metastases","volume":"12","author":"T\u00e9tu","year":"2020","journal-title":"Cancers"},{"key":"B60","doi-asserted-by":"publisher","first-page":"5954","DOI":"10.1038\/s41467-021-25859-y","article-title":"Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis","volume":"12","author":"Brastianos","year":"2021","journal-title":"Nat Commun"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115253","article-title":"Survival improvements in patients with melanoma brain metastases and leptomeningeal disease in the modern era: insights from a nationwide study (2015-2022)","volume":"217","author":"Pedersen","year":"2025","journal-title":"Eur J Cancer"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31629","article-title":"High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma","volume":"124","author":"Faje","year":"2018","journal-title":"Cancer"},{"key":"B63","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1038\/s41591-022-02170-x","article-title":"Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results","volume":"29","author":"Glitza Oliva","year":"2023","journal-title":"Nat Med"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2017-000283","article-title":"Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2","volume":"3","author":"Glitza","year":"2018","journal-title":"ESMO Open"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1227\/neu.0000000000003924","article-title":"Continuous intrathecal infusion of nivolumab in advanced melanoma with concomitant leptomeningeal disease: efficacy, safety, and pharmacokinetics","author":"Faillot","year":"2026","journal-title":"Neurosurgery"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20336","article-title":"Concurrent intrathecal nivolumab and targeted therapy in a patient with melanoma-associated leptomeningeal disease","volume":"39","author":"Chevallier","year":"2025","journal-title":"J Eur Acad Dermatol Venereology"},{"key":"B67","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1186\/s12885-015-1391-x","article-title":"Prolonged survival of a patient with metastatic leptomeningeal melanoma treated with BRAF inhibition-based therapy: a case report","volume":"15","author":"Kim","year":"2015","journal-title":"BMC Cancer"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.885472","article-title":"Current treatment approaches and global consensus guidelines for brain metastases in melanoma","volume":"12","author":"Tan","year":"2022","journal-title":"Front Oncol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.3390\/cancers18040547","article-title":"The use of radiotherapy in leptomeningeal carcinomatosis: a systematic review and random-effects proportions meta-analysis","volume":"18","author":"Ochoa-Lantigua","year":"2026","journal-title":"Cancers (Basel)"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx221","article-title":"EANO\u2013ESMO clinical practice guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours","volume":"28","author":"Le Rhun","year":"2017","journal-title":"Ann Oncol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N Engl J Med"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00612","article-title":"Lifileucel, a tumor-infiltrating lymphocyte therapy, in metastatic melanoma","volume":"39","author":"Sarnaik","year":"2021","journal-title":"J Clin Oncol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-017-0519-6","article-title":"Antibody-drug conjugates (ADCs) for personalized treatment of solid tumors: a review","volume":"34","author":"Lambert","year":"2017","journal-title":"Adv Ther"},{"key":"B74","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12967-020-02212-3","article-title":"Bevacizumab treatment of meningeal melanoma metastases","volume":"18","author":"Simonsen","year":"2020","journal-title":"J Transl Med"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx026","article-title":"Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma","volume":"28","author":"Lee","year":"2017","journal-title":"Ann Oncol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1111\/pcmr.13186","article-title":"Detection of cell-free tumor DNA in cerebrospinal fluid as a diagnostic biomarker for leptomeningeal melanoma metastasis: a case series","volume":"37","author":"Dirven","year":"2024","journal-title":"Pigment Cell Melanoma Res"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1694","article-title":"Single-cell characterization of the immune microenvironment of melanoma brain and leptomeningeal metastases","volume":"27","author":"Smalley","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0000000000000162","article-title":"Cerebrospinal fluid concentrations of vemurafenib in patients treated for brain metastatic BRAF-V600 mutated melanoma","volume":"25","author":"Sakji-Dupr\u00e9","year":"2015","journal-title":"Melanoma Res"},{"key":"B79","doi-asserted-by":"publisher","first-page":"101606","DOI":"10.1101\/2023.12.18.572266","article-title":"Spatial transcriptomics analysis identifies a unique tumor-promoting function of the meningeal stroma in melanoma leptomeningeal disease","volume":"5","author":"Alhaddad","year":"2023","journal-title":"bioRxiv"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.6147","article-title":"Concurrent radiosurgery and systemic therapies for melanoma brain metastases: a systematic review","volume":"11","author":"Weaver","year":"2019","journal-title":"Cureus"},{"key":"B81","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.annonc.2024.11.006","article-title":"Cutaneous melanoma: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"36","author":"Amaral","year":"2025","journal-title":"Ann Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1874139\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T14:21:54Z","timestamp":1790086914000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1874139\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,22]]},"references-count":81,"alternative-id":["10.3389\/fonc.2026.1874139"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1874139","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,22]]},"article-number":"1874139"}}